Effect of Hypercapnia Treatment on Respiratory Recovery After Spinal Cord Injury

NCT ID: NCT05536076

Last Updated: 2024-12-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-01

Study Completion Date

2026-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It is estimated that 1,275,000 people in the United States alone live with spinal cord injury, including around 100,000 Veterans with spinal cord injury, making the V.A. the largest integrated health care system in the world for spinal cord injuries injury care. New therapies are needed to prevent the morbidities and mortalities associated with the high prevalence of respiratory disorders in Veterans with spinal cord injury. The current research project and future studies would set the base for developing innovative therapies for this disorder. This proposal addresses a new therapeutic intervention for sleep apnea in spinal cord injury. The investigators hypothesized that daily hypercapnia treatments improve respiratory symptoms and alleviate sleep apnea in patients with chronic spinal cord injury. The investigators will perform a pilot study to examine the impact of daily hypercapnia treatments for-two week durations among Veterans with spinal cord injury. The investigators believe that this novel approach to treating sleep apnea and will yield significant new knowledge that improves the health and quality of life of these patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

One of the most devastating consequences of cervical spinal cord injury (SCI) is damage to the phrenic motor network, controlling the diaphragm (primary muscle of breathing). Subsequent diaphragm paralysis or paresis results in life-threatening impairments in breathing and can necessitate a need for ventilator assistance. Respiratory and cardiovascular complications are the most common causes of death in the first year post-injury (51% combined). Thus, there is an urgent need to develop strategies for improving function for people with acute and chronic spinal cord injury. Currently, treatments for respiratory dysfunction in spinal cord injury patients are limited to mechanical devices or nerve pacing. Moreover, the proposed plan of studying respiratory muscle training in spinal cord injury patients is novel. However, it is based on animal and human studies that have shown with validity that respiratory muscle training using mild intermittent hypoxia improves respiratory function following SCI. However, the effect of intermittent hypoxia has shown to be dependent on the level of alveolar CO2 and may pose undesirable cardiovascular effects. Previous studies showed that respiratory recovery following SCI manifests by a delayed and partial restorative spontaneous plasticity. The current research project and future anticipated studies would set the base for developing innovative therapies that can stimulate respiratory plasticity hence recovery for this prevalent disorder.

The proposed pilot/feasibility study will test the effect of daily acute intermittent hypercapnia (dAIHc) in individuals with SCI. The objectives of this study are to (1) determine recruitment rates and test the feasibility of recruitment, (2) calculate withdrawal and dropout rates, (3) test the feasibility and tolerability and acceptability of the proposed intervention in an SCI population, (4) develop and refine a new respiratory training intervention using dAIHc paradigm (5) derive effect size estimates for clinical endpoints and their associated variability at the end of treatment to calculate an appropriate sample size for an adequately powered clinical trial. Compared to sham therapy, the central hypothesis is that the daily respiratory muscle training (dAIHc) approach is acceptable and feasible in patients with SCI and will strengthen respiratory muscles and reduce the severity of sleep-disordered breathing (SDB), and will improve daytime symptoms.

This study is highly innovative and the first of its kind in patients with SCI, as it seeks first to use a new set of rehabilitative exercises to improve ventilation and respiratory muscles strength; secondly, it aims to use controlled randomized design; finally, it will determine the role of respiratory muscle exercises in reducing the severity of sleep symptoms and daytime function in SCI. Each aim is independently testable and does not depend on the result of the other aims. The findings will likely apply to a broad range of other neuromuscular diseases (such as Multiple Sclerosis and Stroke). The team of this pilot project has the resources and IRB approval necessary to execute the project.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sleep Apnea SCI/D Hypercapnia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Sleep apnea SCI/D Hypercapnia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Controlled pilot trial to assess the feasibility of using daily chemical stimuli (acute intermittent hypercapnia) in patients with chronic SCI/D in comparison to able-bodied patients with OSA.
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants
Participants (SCI N=10, SD N=10 and Able bodied N=10) will be undergo the intervention arm (acute intermittent hypercapnia)

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention hypercapnia arm

Intermittent hypercapnia treatment five days per week for two weeks.

Group Type ACTIVE_COMPARATOR

Hypercapnia treatment

Intervention Type OTHER

Intermittent hypercapnia treatment five days per week for two weeks.

SCD

Intermittent hypercapnia treatment five days per week for two weeks.

Group Type EXPERIMENTAL

Hypercapnia treatment

Intervention Type OTHER

Intermittent hypercapnia treatment five days per week for two weeks.

Able-Bodoed

Intermittent hypercapnia treatment five days per week for two weeks.

Group Type EXPERIMENTAL

Hypercapnia treatment

Intervention Type OTHER

Intermittent hypercapnia treatment five days per week for two weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hypercapnia treatment

Intermittent hypercapnia treatment five days per week for two weeks.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients with chronic SCI/D (\>6 months post-injury)
* American Spinal Injury Association (ASIA) classification A-D who have evidence of SDB (excluding those with no evidence of a neurologic deficit based on ASIA classification)
* Able-bodied patients (without SCI/D0 who have OSA.

Exclusion Criteria

* Receiving continuous mechanical ventilation (except PAP therapy which is considered usual treatment for SDB
* Severe congestive heart failure with ejection fraction \<35%
* Recent health event that may affect sleep
* stroke
* acute myocardial infarction
* recent surgery
* hospitalization
* Alcohol or substance abuse (\<90 days sobriety)
* Self-described as too ill to engage in study procedures
* Evidence of hypercapnia on spontaneous breathing (end-tidal CO2 \>50 mmHg)
* Unable to provide self-consent for participation
Minimum Eligible Age

18 Years

Maximum Eligible Age

89 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

VA Detroit Healthcare System

UNKNOWN

Sponsor Role collaborator

VA Office of Research and Development

FED

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Abdulghani Sankari, MD PhD

Role: PRINCIPAL_INVESTIGATOR

John D. Dingell VA Medical Center, Detroit, MI

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

John D. Dingell VA Medical Center, Detroit, MI

Detroit, Michigan, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Abdulghani Sankari, MD PhD

Role: CONTACT

Phone: (313) 576-1000

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Abdulghani Sankari, MD PhD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

B4114-P

Identifier Type: -

Identifier Source: org_study_id